Literature DB >> 11554540

Highly efficient random mutagenesis in transcription-reverse-transcription cycles by a hydrogen bond ambivalent nucleoside 5'-triphosphate analogue: potential candidates for a selective anti-retroviral therapy.

K Moriyama1, C Otsuka, D Loakes, K Negishi.   

Abstract

The nucleoside P can base pair with both A and G. We evaluated the mutation frequency induced by the 5'-triphospbate of the ribonucleoside P (PTP) in an in vitro retroviral replication model. After 4 cycles of replication in the presence of PTP, the mutation frequency was raised to 3.8 x 10(-2) per nucleotide and C-to-U and U-to-C mutations were dominantly observed. These results suggest that ambivalent NTP analogues, like PTP, could induce mutations beyond the error threshold of retroviruses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11554540     DOI: 10.1081/NCN-100105242

Source DB:  PubMed          Journal:  Nucleosides Nucleotides Nucleic Acids        ISSN: 1525-7770            Impact factor:   1.381


  4 in total

1.  Mutational robustness of an RNA virus influences sensitivity to lethal mutagenesis.

Authors:  Jason D Graci; Nina F Gnädig; Jessica E Galarraga; Christian Castro; Marco Vignuzzi; Craig E Cameron
Journal:  J Virol       Date:  2011-12-21       Impact factor: 5.103

2.  Therapeutically targeting RNA viruses via lethal mutagenesis.

Authors:  Jason D Graci; Craig E Cameron
Journal:  Future Virol       Date:  2008-11       Impact factor: 1.831

3.  Template properties of mutagenic cytosine analogues in reverse transcription.

Authors:  Tetsuya Suzuki; Kei Moriyama; Chie Otsuka; David Loakes; Kazuo Negishi
Journal:  Nucleic Acids Res       Date:  2006-11-27       Impact factor: 16.971

4.  Lethal mutagenesis of poliovirus mediated by a mutagenic pyrimidine analogue.

Authors:  Jason D Graci; Daniel A Harki; Victoria S Korneeva; Jocelyn P Edathil; Kathleen Too; David Franco; Eric D Smidansky; Aniko V Paul; Blake R Peterson; Daniel M Brown; David Loakes; Craig E Cameron
Journal:  J Virol       Date:  2007-08-08       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.